Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 4
1999 4
2000 1
2001 5
2002 2
2003 1
2004 3
2006 1
2009 2
2011 1
2012 2
2014 1
2015 3
2016 2
2017 1
2018 4
2019 1
2020 1
2024 1
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.
Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW, Giuliano C, Lovati E, Pietra C, Rudd JA. Lu Z, et al. Physiol Behav. 2024 Oct 1;284:114644. doi: 10.1016/j.physbeh.2024.114644. Epub 2024 Jul 21. Physiol Behav. 2024. PMID: 39043357
This study investigated whether ghrelin mimetics, namely anamorelin and ipamorelin, can alleviate weight loss and inhibition of feeding observed during acute and delayed phases of cisplatin-induced emesis in ferrets. The potential of anamorelin to inhibit electrical field …
This study investigated whether ghrelin mimetics, namely anamorelin and ipamorelin, can alleviate weight loss and inhibition of feedi …
Ipamorelin, the first selective growth hormone secretagogue.
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Raun K, et al. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. Eur J Endocrinol. 1998. PMID: 9849822
The development and pharmacology of a new potent growth hormone (GH) secretagogue, ipamorelin, is described. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo. ...A …
The development and pharmacology of a new potent growth hormone (GH) secretagogue, ipamorelin, is described. Ipamore …
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Rahman OF, Lee SJ, Seeds WA. Rahman OF, et al. J Am Acad Orthop Surg Glob Res Rev. 2026 Jan 2;10(1):e25.00236. doi: 10.5435/JAAOSGlobal-D-25-00236. eCollection 2026 Jan 1. J Am Acad Orthop Surg Glob Res Rev. 2026. PMID: 41490200 Free PMC article. Review.
Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-960 …
Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibr …
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.
Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Johansen PB, et al. Growth Horm IGF Res. 1999 Apr;9(2):106-13. doi: 10.1054/ghir.1999.9998. Growth Horm IGF Res. 1999. PMID: 10373343
Ipamorelin is a new and potent synthetic pentapeptide which has distinct and specific growth hormone (GH)-releasing properties. ...The pituitary GH content was unchanged by ipamorelin treatment. Whether ipamorelin or other GH secretagogues may h …
Ipamorelin is a new and potent synthetic pentapeptide which has distinct and specific growth hormone (GH)-releasing pro …
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Gobburu JV, et al. Pharm Res. 1999 Sep;16(9):1412-6. doi: 10.1023/a:1018955126402. Pharm Res. 1999. PMID: 10496658 Clinical Trial.
PURPOSE: To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers. METHODS: A trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14 …
PURPOSE: To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing …
Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.
Johansen PB, Hansen KT, Andersen JV, Johansen NL. Johansen PB, et al. Xenobiotica. 1998 Nov;28(11):1083-92. doi: 10.1080/004982598238976. Xenobiotica. 1998. PMID: 9879640
The pharmacokinetics of three new peptidyl growth hormone secretagogues, ipamorelin (NNC 26-0161), NNC 26-0194 and NNC 26-0235, were compared with two well-known hexapeptides, GHRP-2 and GHRP-6, in the male rat following different routes of administration. 2. …
The pharmacokinetics of three new peptidyl growth hormone secretagogues, ipamorelin (NNC 26-0161), NNC 26-0194 and NNC …
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.
Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Sinha DK, et al. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. Transl Androl Urol. 2020. PMID: 32257855 Free PMC article. Review.
Although testosterone remains the gold standard for hypogonadism management, its benefits are not always conserved across different populations, especially with regards to changes in body composition. Partially in response to this, growth hormone secretagogues (GHS) …
Although testosterone remains the gold standard for hypogonadism management, its benefits are not always conserved across different populati …
Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.
Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. Jiménez-Reina L, et al. Histol Histopathol. 2002;17(3):707-14. doi: 10.14670/HH-17.707. Histol Histopathol. 2002. PMID: 12168778
Growth hormone (GH) is secreted in the anterior pituitary gland by the somatotroph cells. Secretion is regulated by growth hormone releasing hormone (GHRH) and somatostatin. Morever, GH secretagogues (GHS) can exert a considerable effect on GH s …
Growth hormone (GH) is secreted in the anterior pituitary gland by the somatotroph cells. Secretion is regulated by growth …
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.
Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. Andersen NB, et al. Growth Horm IGF Res. 2001 Oct;11(5):266-72. doi: 10.1054/ghir.2001.0239. Growth Horm IGF Res. 2001. PMID: 11735244
The ability of the growth hormone secretagogue (GHS) Ipamorelin to counteract the catabolic effects of glucocorticoid (GC) on skeletal muscles and bone was investigated in vivo in an adult rat model. ...In conclusion, the decrease in muscle strength and bone …
The ability of the growth hormone secretagogue (GHS) Ipamorelin to counteract the catabolic effects of glucocorticoid ( …
41 results